The market is pricing the stock in line with historical averages, assuming steady-state growth.
Fragile underlying quality score of 34/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Mixed fundamental profile with offsetting strengths and weaknesses.
Wall Street sentiment is generally neutral. However, capital return yields remain modest, anchored by a strong, well-covered dividend yield.
LRE struggles with subpar profitability and pressured margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company is facing top-line contraction (-79.5% 3Y CAGR) however, earnings have severely contracted over the same period. Operating efficiency remains adequate with margins around 5.0%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $12.9B | -99.3% | -79.5% | -57.1% | — | |
| EBITDA | $1.1B | — | -77.5% | — | — | |
| Net Income | $481.8M | -99.1% | -78.3% | — | — | |
| EPS (Diluted) | $41.87 | -99.1% | -78.0% | -43.3% | — | |
| Free Cash Flow | $1.4B | +100.8% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 16.4% | 17.1% | 16.2% | 15.4% |
| Operating Margin | 5.0% | 6.0% | 5.6% | 5.0% |
| Net Margin | 3.0% | 3.8% | 3.5% | 3.1% |
| FCF Margin | -7.5% | -4.3% | -8.0% | -7.3% |
Total return is -22.6% (1Y), lagging the benchmark by -47.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -25.1% | -34.4% | — |
| 1Y | -22.6% | -47.6% | +2.5% |
| 3YCAGR | -39.5% | -58.8% | +1.0% |
| 5YCAGR | -26.1% | -38.3% | +1.0% |
| 10YCAGR | -14.0% | -27.5% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about LRE (LRE) valuation, health, and returns.
LRE valuation is being assessed using available models.
Valuation anchors are currently not available.
LRE displays weak financial health with a composite quality score of 34/100, supported by a Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of 0.1%.
LRE pays a 1.5% dividend yield, covered by a 0% payout ratio with 1 years of growth, supplemented by a 0.0% buyback yield.
LRE's current growth trajectory is Decelerating. The company achieved -99.3% 1Y revenue growth and -99.1% 1Y EPS growth, compared to its 3Y revenue CAGR of -79.5%.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
Investment risks for LRE include: -48.2% 1-year max drawdown. Volatility risk is characterized by a beta of 0.93x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.